InsiderTrades.com logo
50-year Wall Street legend: “Sell this tech stock NOW”
From Chaikin Analytics   |   Ad
Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies.
You can watch for it for free, right here.

CALC Insider Trading

Insider Ownership Percentage: 41.55%
Insider Buying (Last 12 Months): $4,634,998.09
Insider Selling (Last 12 Months): $0.00

CalciMedica Insider Trading History Chart

This chart shows the insider buying and selling history at CalciMedica by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CalciMedica Share Price & Price History

Current Price: $3.45
Price Change: +0.30 (1.20%)
As of 11/22/2024 01:00 AM ET

This chart shows the closing price history over time for CALC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
2025: Digital Asset Insights You Need to Know
From Darwin   |   Ad
Cryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.
Get your guide today!

CalciMedica Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/1/2024A. Rachel LehenyCEOBuy20,000$3.75$75,000.00130,926View SEC Filing Icon  
11/1/2024Eric W RobertsInsiderBuy53,333$3.75$199,998.75164,706View SEC Filing Icon  
11/1/2024Fred A MiddletonDirectorBuy87,744$3.75$329,040.00814,300View SEC Filing Icon  
11/1/2024Sanderling Venture Partners ViMajor ShareholderBuy86,867$3.75$325,751.25814,300View SEC Filing Icon  
8/27/2024A. Rachel LehenyCEOBuy1,000$4.19$4,190.00110,926View SEC Filing Icon  
8/23/2024Eric W RobertsInsiderBuy5,000$3.57$17,850.0046,894View SEC Filing Icon  
8/23/2024Robert N WilsonDirectorBuy54,000$3.72$200,880.00364,196View SEC Filing Icon  
8/21/2024Eric W RobertsInsiderBuy5,000$4.04$20,200.0044,894View SEC Filing Icon  
6/27/2024Eric W RobertsInsiderBuy5,000$3.22$16,100.0010,223View SEC Filing Icon  
6/27/2024Robert N WilsonDirectorBuy8,443$3.23$27,270.89258,918View SEC Filing Icon  
4/1/2024Eric W RobertsInsiderBuy746$3.90$2,909.4036,640View SEC Filing Icon  
1/23/2024Fred A MiddletonDirectorBuy679,384$3.70$2,513,720.80946,744View SEC Filing Icon  
1/23/2024Sanderling Venture Partners ViMajor ShareholderBuy243,356$3.70$900,417.20946,744View SEC Filing Icon  
12/11/2023Robert N WilsonDirectorBuy506$3.30$1,669.80182,161View SEC Filing Icon  
11/6/2023A. Rachel LehenyCEOBuy2,440$3.12$7,612.8016,840View SEC Filing Icon  
11/6/2023Eric W RobertsInsiderBuy2,400$3.12$7,488.0035,894View SEC Filing Icon  
11/3/2023A. Rachel LehenyCEOBuy5,000$2.85$14,250.0014,400View SEC Filing Icon  
11/3/2023Eric W RobertsInsiderBuy3,200$2.80$8,960.0016,587View SEC Filing Icon  
8/25/2023Eric W RobertsInsiderBuy736$3.18$2,340.485,000View SEC Filing Icon  
8/21/2023Eric W RobertsInsiderBuy1,750$3.25$5,687.503,550View SEC Filing Icon  
6/26/2023Eric W RobertsInsiderBuy1,200$3.70$4,440.0013,387View SEC Filing Icon  
6/23/2023Eric W RobertsInsiderBuy500$3.35$1,675.0016,185View SEC Filing Icon  
See Full Table
917 Trades… Zero Losses?
From Insiders Exposed   |   Ad
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
Go here to see how you can start accessing these opportunities today

SEC Filings (Institutional Ownership Changes) for CalciMedica (NASDAQ:CALC)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CALC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

CalciMedica Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2024Geode Capital Management LLC66,553$0.30M0.0%+51.2%0.619%Search for SEC Filing on Google Icon
11/5/2024BML Capital Management LLC153,887$0.68M0.4%-4.1%1.432%Search for SEC Filing on Google Icon
11/1/2024Atria Investments Inc26,503$0.12M0.0%+136.5%0.247%Search for SEC Filing on Google Icon
4/23/2024BML Capital Management LLC160,424$0.67M0.4%+10.3%1.494%Search for SEC Filing on Google Icon
2/2/2024Meritage Portfolio Management46,000$0.13M0.0%+360.0%0.810%Search for SEC Filing on Google Icon
1/30/2024BML Capital Management LLC145,424$0.42M0.3%+63.8%2.560%Search for SEC Filing on Google Icon
12/7/2023Hudson Bay Capital Management LP166,857$0.43M0.0%N/A2.938%Search for SEC Filing on Google Icon
7/31/2023Meritage Portfolio Management10,000$40K0.0%N/A0.177%Search for SEC Filing on Google Icon
7/24/2023BML Capital Management LLC88,781$0.36M0.3%N/A1.568%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
CalciMedica logo
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
Read More on CalciMedica

Today's Range

Now: $3.45
Low: $3.41
High: $3.48

50 Day Range

MA: $3.94
Low: $3.33
High: $4.99

52 Week Range

Now: $3.45
Low: $2.68
High: $8.38

Volume

27,222 shs

Average Volume

96,630 shs

Market Capitalization

$46.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Who are the company insiders with the largest holdings of CalciMedica?

CalciMedica's top insider investors include:
  1. Fred A Middleton (Director)
  2. Sanderling Venture Partners Vi (Major Shareholder)
  3. Robert N Wilson (Director)
  4. Eric W Roberts (Insider)
  5. A Rachel Leheny (CEO)
Learn More about top insider investors at CalciMedica.

Who are the major institutional investors of CalciMedica?

CalciMedica's top institutional investors include:
  1. BML Capital Management LLC — 1.43%
  2. Geode Capital Management LLC — 0.62%
  3. Atria Investments Inc — 0.25%
Learn More about top institutional investors of CalciMedica stock.

Which institutional investors are selling CalciMedica stock?

Within the last quarter, CALC stock was sold by these institutional investors:
  1. BML Capital Management LLC

Which institutional investors are buying CalciMedica stock?

In the last quarter, CALC stock was purchased by institutional investors including:
  1. Geode Capital Management LLC
  2. Atria Investments Inc
Within the previous year, these company insiders have bought CalciMedica stock:
  1. Fred A Middleton (Director)
  2. Sanderling Venture Partners Vi (Major Shareholder)
  3. Robert N Wilson (Director)
  4. Eric W Roberts (Insider)
  5. A Rachel Leheny (CEO)
Learn More investors buying CalciMedica stock.
50-year Wall Street legend: “Sell this tech stock NOW”
From Chaikin Analytics   |   Ad
Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies.
You can watch for it for free, right here.